OBJECTIVE: This study operationalized and measured the external validity, or generalizability, of studies on mental health treatment and outcomes published in four journals between 1981 and 1996. METHOD: MEDLINE was searched for articles on mental health treatment and outcomes that were published in four leading psychiatry and psychology journals between 1981 and 1996. A 156-item instrument was used to assess generalizability of study findings. RESULTS: Of more than 9,000 citations, 414 eligible studies were identified. Inclusion of community sites and patients from racial or ethnic minority groups were documented in only 12 and 25 percent of studies, respectively. Random or systematic sampling methods were rare (3 percent), and 75 percent of studies did not explicitly address sample representativeness. Studies with funding from the National Institute of Mental Health (NIMH) were more likely than those without NIMH funding to document the inclusion of patients from minority groups (30 percent compared with 20 percent). Randomized studies were more likely than nonrandomized studies to document the inclusion of patients from minority groups (28 percent compared with 17 percent), include patients with comorbid psychiatric conditions (31 percent compared with 19 percent), and attend to sample representativeness (28 percent compared with 15 percent). Modest improvements were seen over time in inclusion of patients from minority groups, inclusion of patients with psychiatric comorbidities, and attention to sample representativeness. CONCLUSIONS: Generalizability of studies on treatments and outcomes, whether experimental or observational, remained low and poorly documented over the 16-year period.
OBJECTIVE: This study operationalized and measured the external validity, or generalizability, of studies on mental health treatment and outcomes published in four journals between 1981 and 1996. METHOD: MEDLINE was searched for articles on mental health treatment and outcomes that were published in four leading psychiatry and psychology journals between 1981 and 1996. A 156-item instrument was used to assess generalizability of study findings. RESULTS: Of more than 9,000 citations, 414 eligible studies were identified. Inclusion of community sites and patients from racial or ethnic minority groups were documented in only 12 and 25 percent of studies, respectively. Random or systematic sampling methods were rare (3 percent), and 75 percent of studies did not explicitly address sample representativeness. Studies with funding from the National Institute of Mental Health (NIMH) were more likely than those without NIMH funding to document the inclusion of patients from minority groups (30 percent compared with 20 percent). Randomized studies were more likely than nonrandomized studies to document the inclusion of patients from minority groups (28 percent compared with 17 percent), include patients with comorbid psychiatric conditions (31 percent compared with 19 percent), and attend to sample representativeness (28 percent compared with 15 percent). Modest improvements were seen over time in inclusion of patients from minority groups, inclusion of patients with psychiatric comorbidities, and attention to sample representativeness. CONCLUSIONS: Generalizability of studies on treatments and outcomes, whether experimental or observational, remained low and poorly documented over the 16-year period.
Authors: Mayumi Okuda; Deborah S Hasin; Mark Olfson; Sharaf S Khan; Edward V Nunes; Ivan Montoya; Shang-Min Liu; Bridget F Grant; Carlos Blanco Journal: Drug Alcohol Depend Date: 2010-05-26 Impact factor: 4.492
Authors: Jodi M Gonzalez; Dharma E Cortés; Tamara Reeves; Rob Whitley; Linda Lopez; Gary R Bond; Dawn I Velligan; Alexander L Miller Journal: Community Ment Health J Date: 2011-03-20
Authors: Angela M Bengtson; Brian W Pence; Bradley N Gaynes; E Byrd Quinlivan; Amy D Heine; Julie K OʼDonnell; Heidi M Crane; W Christopher Mathews; Richard D Moore; Daniel Westreich; Conall OʼCleirigh; Katerina Christopoulos; Matthew J Mimiaga; Michael J Mugavero Journal: J Acquir Immune Defic Syndr Date: 2016-12-01 Impact factor: 3.731